2-[2-(4-methylpiperazin-1-yl)ethyl]-6H-pyrrolo[3,2-e][1,3]benzoxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 2-[2-(4-methylpiperazin-1-yl)ethyl]-6H-pyrrolo[3,2-e][1,3]benzoxazole
• 化学式: C₁₆H₂₀N₄O
• 分子量: 284.36
• InChiKey: SPFWHUJSJQVRMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  48.3
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• 6H-oxazolo[4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
  申请人：Schiemann Kai

  公开号：US20050101649A1

  公开（公告）日：2005-05-12

  Compounds of the formula I in which R 1 , R 2 , R 3 and R 4 are as defined in claim 1, are ligands of the nicotinic acetylcholine receptor and/or serotonergic ligands and are suitable for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia anorexia nervosa or other eating disorders, compulsvie behaviour, premenstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds, and for the treatment of disorders which are characterised by an excess of circulating serotonin or by serotonergic hyperactivity.

  公式I中的化合物，其中R1、R2、R3和R4如权利要求1所定义，是尼古丁乙酰胆碱受体和/或血清素配体的配体，适用于预防或治疗精神病、精神分裂症、抑郁症、焦虑状态、痴呆症，特别是阿尔茨海默病和Lewy小体痴呆、神经退行性疾病、帕金森病、肌萎缩性侧索硬化症、亨廷顿病、图雷特综合症、学习和记忆限制、暴食症厌食症或其他进食障碍、强迫行为、经前期综合症、年龄引起的记忆障碍、改善尼古丁依赖的戒断症状、中毒化合物引起的中风或脑损伤，并用于治疗其特征为循环血清素过多或血清素活性过高的疾病。
• 6H-Oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
  申请人：Schiemann Kai

  公开号：US20080051394A1

  公开（公告）日：2008-02-28

  Compounds of the formula I in which R 1 , R 2 , R 3 and R 4 are as defined in Claim 1, are ligands of the nicotinic acetylcholine receptor and/or serotonergic ligands and are suitable for the prophylaxis or treatment of psychoses, schizophrenia, depression, anxiety states, dementia, in particular Alzheimer's disease and Lewy bodies dementia, neurodegenerative disorders, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, Tourette's syndrome, learning and memory restrictions, bulimia, anorexia nervosa or other eating disorders, compulsive behaviour, premenstrual syndrome, age-induced memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds, and for the treatment of disorders which are characterised by an excess of circulating serotonin or by serotonergic hyperactivity.

  公式I中的化合物，其中R1、R2、R3和R4如权利要求1所定义，是尼古丁乙酰胆碱受体和/或血清素配体的配体，适用于预防或治疗精神病、精神分裂症、抑郁症、焦虑状态、痴呆症，特别是阿尔茨海默病和Lewy小体痴呆、神经退行性疾病、帕金森病、肌萎缩性侧索硬化、亨廷顿病、抽动症、学习和记忆障碍、暴食症、厌食症或其他进食障碍、强迫行为、经前综合征、年龄引起的记忆障碍、改善尼古丁依赖的戒断症状、中毒化合物引起的中风或脑损伤，并用于治疗其特征为循环血清素过多或存在血清素活性亢进的疾病。
• 6H-OXAZOLO 4,5-E]INDOLE DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND/OR SEROTONERGIC LIGANDS
  申请人：MERCK PATENT GmbH

  公开号：EP1392699A1

  公开（公告）日：2004-03-03
• US7291633B2
  申请人：——

  公开号：US7291633B2

  公开（公告）日：2007-11-06
• US7741343B2
  申请人：——

  公开号：US7741343B2

  公开（公告）日：2010-06-22